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studyquestion: Do any proteomic biomarkers previously identiﬁed for pre-eclampsia (PE) overlap with those identiﬁed in women with
polycystic ovary syndrome (PCOS).
summaryanswer: Five previously identiﬁed proteomic biomarkers were found to be common in womenwith PE and PCOSwhen com-
pared with controls.
what is known already: Various studies have indicated an association between PCOS and PE; however, the pathophysiological
mechanisms supporting this association are not known.
study design, size, duration: A systematic review and update of our PCOS proteomic biomarker database was performed, along
with a parallel review of PE biomarkers. The study included papers from 1980 to December 2013.
participants/materials, setting, methods: In all the studies analysed, therewere a total of 1423patients and controls. The
number of proteomic biomarkers that were catalogued for PE was 192.
main results and the role of chance: Five proteomic biomarkerswere shown tobe differentially expressed inwomenwith PE
and PCOSwhen comparedwith controls: transferrin, ﬁbrinogena,b and g chain variants, kininogen-1, annexin 2 and peroxiredoxin 2. In PE, the
biomarkers were identiﬁed in serum, plasma and placenta and in PCOS, the biomarkers were identiﬁed in serum, follicular ﬂuid, and ovarian and
omental biopsies.
limitations, reasons forcaution: The techniquesemployed todetect proteomics have limited ability in identifying proteins that
areof lowabundance, someofwhichmayhave a diagnostic potential. The sample sizes andnumberof biomarkers identiﬁed from these studies do
not exclude the risk of false positives, a limitation of all biomarker studies. The biomarkers common to PE and PCOSwere identiﬁed from prote-
omic analyses of different tissues.
wider implications of the findings: This data amalgamation of the proteomic studies in PE and in PCOS, for the ﬁrst time, dis-
covered a panel of ﬁve biomarkers for PE which are common to women with PCOS, including transferrin, ﬁbrinogen a, b and g chain variants,
kininogen-1, annexin 2 and peroxiredoxin 2. If validated, these biomarkers could provide a useful framework for the knowledge infrastructure in
this area. To accomplish this goal, a well co-ordinated multidisciplinary collaboration of clinicians, basic scientists and mathematicians is vital.
study funding/competing interest(s): No ﬁnancial support was obtained for this project. There are no conﬂicts of interest.
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Introduction
Polycystic ovary syndrome (PCOS) is the most common endocrine
disorder of women of reproductive age. PCOS can present as infertility,
oligomenorrhoea, hirsuitism, acne, hyperandrogenaemia and/or
obesity and have metabolic consequences such as an increased risk of
hypertension, insulin resistance and type 2 diabetes in later life (Dunaif
and Thomas, 2001; Wild, 2002; Rotterdam ESHRE/ASRM-Sponsored
PCOS Consensus Workshop Group, 2004). Women with PCOS are
also known to have an increased risk of obstetric complications including
pre-eclampsia (PE), gestational diabetes and preterm birth (Mikola et al.,
2001; Boosma et al., 2006; Altieri et al., 2010; Kjerulff et al., 2011;Galazis
et al., 2013).
A systematic review performed recently showed that the pregnant
women who are known to have PCOS were four times more likely to
developPEwhencomparedwith controls (Kjerulff et al., 2011).Although
the association between PCOS and PE has been documented, the
underlying pathophysiological mechanisms involved are not completely
understood; however, it is possible that the raised androgen levels,
hyperinsulinaemia and subsequent diabetic andhypertensive susceptibil-
ities in PCOS may act as co-factors (Troisi et al., 2003). Among the
various implicating factors, defective placental vasculature appears to
be central to the disease (Duckitt and Harrington, 2005).
Currently, there is insufﬁcient evidence to establish causation and to
establish screening for patients for these complications, solely based
on PCOS diagnosis. There is however a need for research studies into
the molecular mechanisms underpinning the link between PCOS and
PE. This could facilitate screening in women with PCOS for PE, which
could minimize the occurrence of maternal and fetal morbiditiy/mortal-
ity associated with PE in pregnant women with PCOS. Proteomic bio-
marker discovery programmes may address this need.
PE is pregnancy-induced hypertension in association with proteinuria
(.0.3 g in 24 h)withorwithoutoedema (RoyalCollegeofObstetricians
and Gynaecologists, 2006). Virtually, any organ systemmay be affected.
The incidence of severe PE is5 in 1000maternities and is amajor cause
of poor pregnancy outcomes, including severe obstetric morbidity and
maternal and fetal mortality (Royal College of Obstetricians and Gynae-
cologists, 2006). PE is associated with fetal growth restriction, low birth-
weight, preterm delivery and respiratory distress syndrome (Royal
College of Obstetricians and Gynaecologists, 2006). Pregnant women
who are at high risk of developing PE can be identiﬁed in the early ante-
natal period from a comprehensive history enquiring about risk factors,
including previous history or family history of PE, age and BMI as well as
co-morbidities such as hypertension, renal disease and diabetes (Duckitt
and Harrington, 2005). PE is still the second most common cause of
maternal mortality as reported by the conﬁdential enquiry into Maternal
and Child Health for the triennium of 2006–2008 (CMACE, 2011). The
exact pathophysiological mechanism of PE is still unknown.
Proteomics is an emerging discipline which involves the global analysis
of protein expression changes (Anderson andAnderson, 1998). There is
a common consensus that the information obtained from the protein
component of the cell or tissue complements the genomic data. Altera-
tions in proteinexpressiondepict biological processes as proteins are the
vital elements that control cell function. Proteomic methods are appro-
priate to detect post-translational alterations. In a literature review
of MEDLINE (1966–December 2013), EMBASE (1980–December
2013), ISI web of knowledge (v4.2) and Cochrane (1993–December
2013) databases combining the terms: ‘proteomics’, ‘proteomic’, ‘pre-
eclampsia’, and ‘PCOS’ or ‘polycystic ovary syndrome’, no studies
were isolated, where proteomic biomarkers for PE had been speciﬁcally
investigated in women with PCOS. However, several studies were iden-
tiﬁed where proteomic techniques had been used in the study of preg-
nant women with PE and in women with PCOS as separate entities.
The present study aimed at systematically reviewing the research
undertaken using proteomic technologies for thedetectionof proteomic
biomarkers in PE and considerwhether anyof these biomarkers could be
used as candidate biomarkers for identifying thewomenwith PCOSwho
are at risk of developing PE in pregnancy. This was achieved by perform-
ing a comparison of PE biomarkers against previously a published data-
base of all proteomic biomarkers identiﬁed so far in women with
PCOS (Atiomo et al., 2009). Any biomarkers found to be common to
both conditions could be investigated in future studies to understand
the mechanisms that link PE with PCOS.
Methods
This study did not involve patient contact; hence, Institutional Review Board
(IRB) approval was not mandatory.
Studies eligible for review
MEDLINE (1966–December 2013), EMBASE (1980–December 2013),
Cochrane (1993–December 2013) and ISI web of knowledge (v4.2) data-
bases were searched using the terms ‘proteomics’, ‘proteomic’, ‘pre-
eclampsia’, ‘pre-eclamptic toxemia’, ‘proteomic biomarker’, and ‘polycystic
ovary syndrome’ without any restrictions. Animal studies were not included
in the review.
Data abstraction
The original PDFs of studies were acquired through online links to the ﬁles
obtained from the search results. The references from the studies were
manually searched to identify any other relevant studies. The search criterion
ended in December 2013. The searches were independently conducted by
two of the authors (G.H.K. and N.D.).
Main characteristics of the PE studies
The selected studies were assessed and a record was made of the speciﬁc
study characteristics including type of study, design, number of participants
(n), typeof proteomic techniqueused and theexact natureof the sample ana-
lysed in each study (whether serum, urine etc.). A list of proteinswas created,
that were identiﬁed to have been expressed differently in women with PE
versus controls (normal pregnancy). These parameters are presented in
Table I. To improve accuracy, the studies were screened independently by
two of the co-authors (G.H.K., N.D.).
Methodological quality assessment
The QUADOMICS tool, which is an adaptation of QUADAS (a quality as-
sessment tool for use in systematic reviews of the diagnostic accuracy
studies) takes into account the particular challenges encountered using
‘omics’ based techniques (Parker et al., 2010) and is recommended in
studies using thismethodology. The tool was applied to determine themeth-
odological quality of the studies included in this systematic review (Table II).
The studies that achieved the score of 12/16 were classiﬁed as high quality
(HQ), whereas those which scored 11/16 or less were classiﬁed as low
quality (LQ). The methodological quality assessment was also performed
independently by two of the co-authors (G.H.K. and N.D.).
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Table I Themain characteristics of each study and the proteins differentially expressed in patients with PE compared with normal individuals.
Study Population Selection criteria Proteins identiﬁed Change
versus
control
(/)
Sample
site
Technique used
n Mean
age+ SD
age range
Inclusion Exclusion
Epiney et al.
(2012)
Control, n ¼ 6 33.2+ 2.6 Normotensive pregnant patients NA FN1 protein Decreased Placenta LC-ESI-MS/MS
PE, n ¼ 4 38.8+ 2.3 Systolic blood pressure level ≥ 160 mmHg or a
diastolic blood pressure level ≥ 110 mmHg on
two occasions and proteinuria ≥3+ on a urine
stick or ≥5 g in a 24-h urine specimen (ACOG
practice, 2002)
a-Actinin-4 Decreased
Actin Increased
Transgelin-2 Decreased
Pregnancy-speciﬁc b-1-glycoprotein 3 Increased
Choriogonadotrophin subunit b Increased
Pregnancy-speciﬁc b-1-glycoprotein 2 Increased
Protein Si00-A11 Decreased
Pregnancy-speciﬁc b-1-glycoprotein 4 Increased
Phosphatidylethanolamine-binding
protein 1
Decreased
b-2-microglobulin Decreased
Coagulation factor XIII A chain Decreased
Follistatin-related protein 1 Decreased
Malate dehydrogenase Increased
Annexin A2 Decreased
Thioredoxin domain-containing protein 4 Decreased
Serotransferrin Decreased
C9orf88 variant protein (Fragment) Increased
Cystatin-M Decreased
Polypyrimidine tract-binding protein 1 Decreased
40S ribosomal protein S5 Increased
Calnexin Decreased
Serine/threonine-protein phosphatase
2A65 kDa regulatory subunitAa isoform
Increased
Buhimschi
et al. (2008)
38 ¼ PE
21 ¼ control
NA Severe PE (sPE) NA 21-aa C-terminus fragment of
SERPINA-1
Increased Urine+
Placenta
SELDI-TOF-MS
206 (cross-sectional
cohort)
19 (longitudnal
cohort)
Low risk of PE (n ¼ 4)
High risk of PE (n ¼ 15)
24-aa N-terminus fragment of
SERPINA-1
Increased
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Table I Continued
Study Population Selection criteria Proteins identiﬁed Change
versus
control
(/)
Sample
site
Technique used
n Mean
age+ SD
age range
Inclusion Exclusion
Park et al.
(2008)
PE, n ¼ 18 32.5+ 4.7 Blood pressure ≥140/90 after 20 weeks and
proteinuria
Multiple pregnancy Proapolipoprotein A-I Increased Amniotic
ﬂuid
SELDI-TOF-MS
Chronic
hypertension, n ¼ 7
33.0+ 4.5 Blood pressure ≥140/90 before pregnancy or
after 20 weeks
Evidence of intrauterine
infection
SBBI42 Increased Western blot
Control, n ¼ 16 31.6+ 3.0 No evidence of high blood pressure or
proteinuria
Johnstone
et al. (2011)
Control, n ¼ 6 NA No evidence of high blood pressure or
proteinuria
Smokers Diabetes
IUGR Medication other
than antihypertensives
a-2-HS-glycoprotein Increased Placenta LC-MS/MS
PE, n ¼ 6 Blood pressure ≥140/90 after 20 weeks and
proteinuria
Glutathione S-transferase Decreased Western blot
Peroxiredoxin 6 Decreased
Aldose reductase Decreased
Heat shock protein 60 Decreased
b-Tubulin Decreased
Heat shock protein 70 Decreased
Proteasome, a subunit Decreased
Ezrin Decreased
Protein disulphide isomerize Decreased
Phosphoglycerate mutase 1 Decreased
Triosephosphate isomerase Decreased
Gharesi et al.
(2010)
Normal, n ¼ 5 24.1+ 3 No evidence of high blood pressure or
proteinuria
Multigravida Heat shock protein gp96 precursor Decreased Placenta MALDI TOF/TOF
sPE, n ¼ 5 24.3+ 2.4 Blood pressure, 160 mmHg or higher systolic or
110 mmHg or higher diastolic on two occasions
at least 6 h apart, and new onset of proteinuria,
500 mg or more of protein in a 24 h urine
collection or 3+ or greater on urine dipstick
testing of two random urine samples collected at
least 4 h apart
Vaginal birth Chloride intracellular channel 3 Increased
Chain A of enoyl-co-enzyme A hydratase Decreased
Chain A, crystal structure of human
Apolipoprotein A-I
Decreased
Protein disulphide isomerase Increased
Cu/Zn-superoxide dismutase Increased
Actin, g 1 pro-peptide Decreased
Peroxiredoxin 3, isoform CRA-a Decreased
HSPA8 (Hsc 70) Decreased
Peroxiredoxin 2 isoform a Decreased
Chain A, Transthyretin Decreased
Blumenstein
et al. (2009a)
Normal, n ¼ 57 29.7 Plasma obtained at 20+1 week gestation from
the SCOPE biobank. No evidence of high blood
pressure or proteinuria
NA Fibronectin 1 isoform 3 preproprotein Increased Serum LC-MS/MS
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PE (appropriate
growth for
gestation), n ¼ 27
30 Blood pressure≥140/90 after 20weeks on two
occasions 4 h apart and combined with either
proteinuria or multi-organ complication
Fibrinogen, b chain preproprotein Increased Western Blot
PE (small for
gestation age),
n ¼ 12
30.3 Customized birthweight less than tenth centile
for gestational age
Clusterin isoform 1 Increased
TTR Increased
Apolipoprotein A-I precursor Increased
Hemopexin Increased
Transferrin Increased
Watanabe
et al. (2004)
Normal pregnant
women n ¼ 80
30.3+ 4.3 No evidence of high blood pressure or
proteinuria
NA Fibrinogen g chain Increased Serum 2-Dimensional
electrophoresis
MALDI-TOF-MS
Western Blot
PE n ¼ 80 30.6+ 5.3 Diagnosis of PE was based on the criteria of the
National High Blood Pressure Education
ProgramWorking Group on High Blood
Pressure in Pregnancy
a-1-antichymotrypsin Increased
Blankley et al.
2009
Normal pregnant
n ¼ 23
NA No evidence of high blood pressure or
proteinuria
NA Clusterin Increased Plasma MALDI TOF/TOF
PE n ¼ 23 PEwas diagnosed using standard deﬁnitions from
the International Society for the Study of
Hypertension in Pregnancy
Apolipoprotein B Increased
Inter-a inhibitor H1 Increased
Inter-a inhibitor H2 Increased
Inter-a inhibitor H3 Increased
Complement C6 Increased
Complement C7 Increased
PAPP-A Increased
Vitamin K-dependent protein Z Increased
Complement C1s Increased
Sex hormone-binding globulin Increased
Clusterin Increased
Coagulation factor X Increased
Coagulation factor V Increased
Insulin-like growth factor binding protein
complex acid labile chain precursor (ALS)
Increased
Pregnancy-speciﬁc B-1 glycoprotein 11 Increased
Pregnancy-speciﬁc B-1 glycoprotein 1 Increased
Vitamin D binding proteina Increased
Serum amyloid P-component Increased
Complement C2 Increased
Pregnancy-speciﬁc glycoprotein 9 Increased
Paraoxonase 1 Increased
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Table I Continued
Study Population Selection criteria Proteins identiﬁed Change
versus
control
(/)
Sample
site
Technique used
n Mean
age+ SD
age range
Inclusion Exclusion
Peroxiredoxin-2 Increased
Carboxypeptidase N catalytic chain Decreased
Vitamin D binding protein Decreased
a-2-macroglobulin Decreased
Vitronectin precursor Decreased
Afamin precursor (a-albumin) Decreased
Fibronectin 1 Decreased
Trypsin-1 Decreased
Extracellular matrix protein 1 Decreased
Complement C1q Decreased
Plasma protease C1 inhibitor Decreased
Fetuin-A Decreased
Zinc ﬁnger protein Decreased
Complement C 4B Decreased
Liu et al.
(2011)
Normal pregnant
n ¼ 5
28.2+ 1.8 No evidence of high blood pressure or
proteinuria
NA Serpin peptidase inhibitor, clade A,
member 1
Increased Plasma LC-MS/MS
sPE n ¼ 5 30.3+ 2.4 Severe PE was deﬁned as increased blood
pressure (≥160 mmHg systolic or≥110 mmHg
diastolic on ≥2 occasions at least 6 h apart) that
occurred after 20 weeks of gestation in women
with preciously normal blood pressure,
accompanied with proteinuria (≥5 g/24 h) or
proteinuria of 2+ or more by dipstick
measurement
a-2-HS-glycoprotein Increased
AMBP protein Increased
Apolipoprotein E Increased
Apolipoprotein H Increased
Ceruloplasmin Increased
Chorionic somatomammotropin
hormone
Increased
Clusterin Increased
Coagulation factor X Increased
Complement C1q subcomponent
subunit A
Increased
Complement C1q subcomponent
subunit C
Increased
Complement component C8 b chain Increased
Complement component C9 Increased
Complement factor H Increased
Complement factor H-related 1 Increased
Complement factor properdin Increased
Fibrinogen a chain Increased
Fibrinogen b chain Increased
Fibrinogen g chain Increased
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Fibronectin Increased
Fibulin-1 Increased
Galectin-3-binding protein Increased
Hyaluronan-binding protein 2 Increased
Kininogen-1 Increased
Lysozyme C Increased
Serpin peptidase inhibitor, clade F,
member 1
Increased
Plasminogen Increased
Pregnancy-speciﬁc b-1-glycoprotein 3 Increased
Pregnancy-speciﬁc b-1-glycoprotein 4 Increased
Vitamin D-binding protein Increased
Vitronectin Increased
a-2-macroglobulin Increased
Angiogenin Increased
Serpin peptidase inhibitor, clade C,
member 1
Increased
Apolipoprotein A-II Decreased
Apolipoprotein B-100 Decreased
Apolipoprotein-L1 Decreased
C4b-binding protein a chain Decreased
Complement factor H-related
protein 1
Decreased
Glutathione peroxidase 3 Decreased
Haemoglobin subunit a Decreased
Haemoglobin subunit 6 Decreased
Leucine-rich repeat-containing
protein 6
Decreased
Mannan-binding lectin serine
protease 2
Decreased
Plasma retinol-binding protein 4 Decreased
Platelet factor 4 Decreased
Pregnancy zone protein Decreased
Serum amyloid A2 protein Decreased
Serum amyloid A-4 protein Decreased
Serum amyloid P-component Decreased
Transthyretin Decreased
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Table I Continued
Study Population Selection criteria Proteins identiﬁed Change
versus
control
(/)
Sample
site
Technique used
n Mean
age+ SD
age range
Inclusion Exclusion
Total ¼ 267 Working Group Criteria on high blood pressure
in pregnancy
NA Matrix metalloprtoteinase-9 Decreased Decreased 2D-LC-MS/MS
Rasanen et al.
(2010)
Clinical Cohort:118
Mild PE n ¼ 30
28.3
Fibronectin Increased
Severe PE n ¼ 30 27.8 Pappalysin-2 Increased
Normotensive
n ¼ 58
28.8 Choriogonadotrophin-b Increased
Preclinical cohort:
n ¼ 149 Mild PE
n ¼ 30
Apolipoprotein C III Increased
sPE n ¼ 40 Cystatin C Increased
Normotensive
n ¼ 79
sFlt-1 Increased
sPE n ¼ 8 Endoglin Increased
Pre clinical cohort
Complement factor D Increased
Vascular cell adhesion protein 1 Increased
b-2-microglobulin Increased
Cystatin-C Increased
Pappalysin Decreased
Control n ¼ 8 NA Normotensive pregnant women NA Heat shock 27 kDa protein 1 Increased Placenta LC-MS/MS
Jin et al. 2008 PE n ¼ 8 Hypertension was deﬁned as a blood pressure
.140 mm/Hg (systolic) or .90 mm/Hg
(diastolic) on at least two occasions and at least
4–6 h apart after the 20th week of gestation in
women known to be normotensive beforehand
78 kDa glucose-regulated protein
precursor
Increased
Titin Decreased
Prohibitin Increased
Calnexin Decreased
Annexin A1 Increased
NADH-ubiquinone oxidoreductase 24
kDa
Increased
Chloride intracellular channel protein 3 Increased
Smooth muscle and non-muscle myosin
alkali light chain isoform 1
Increased
Actin a 1 skeletal muscle protein Increased
Keratin 10 Increased
Centrosome pr Increased
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Vascotto et al.
(2007)
Controls n ¼ 5 35 years Normotensive and women diagnosed with PE Women with
pre-gestational diseases
and pregnancy
complications
Transthyretin Increased Amniotic
ﬂuid
MALDI-TOF-MS
PE n ¼ 5 35years
Myers et al.
(2013)
Taining set Controls
n ¼ 200
26.8 (6.4) Normotensive patients NA IGFALS Increased Plasma MS-MALDI
PE n ¼ 100 26.6 (6.0) PE ¼ hypertension associated with proteinuria.
Hypertension was deﬁned as a blood pressure
.140 mm/Hg (systolic) or .90 mm/Hg
(diastolic) on at least two occasions and at least
4–6 h apart after the 20th week of gestation in
women known to be normotensive beforehand
MCAM Decreased
Validation set
Controls n ¼ 250
28.9 (5.3) Proteinuria ¼ renal excretion of at least 300 mg
of proteins in a 24 h urine sample
PE n ¼ 50 29.7 (5.5)
Centlow et al.
(2010)
Control n ¼ 30 35.1 No evidence or previous history of PE Patients with other
systemic diseases
Apolipoprotein 1 Increased Placenta MALDI –TOF MS/
2-DPAGE/Western
blot
PE n ¼ 30 35.1 PE was deﬁned as systolic blood pressure
≥140 mmHg or diastolic blood pressure
≥90 mmHg, or both, on 2 occasions 4 h apart
after 20 weeks’ gestation but before the onset of
labour, or post-partum, with either proteinuria
(24-h urinary protein ≥300 mg or spot urine
protein:creatinine ratio ≥30 mg/mmol
creatinine or urine dipstick protein ++) or any
multisystem complication of PE
Tropomyosin -3 Decreased
Kolla et al.
(2012)
Control n ¼ 6 30.7 (2.9) Normotensive NA Fibrinogen Fragment D Increased Plasma MALDI-TOF/TOF
iTRAQ
PE n ¼ 6 31.7 (1.8) PE ¼ blood pressure above 140/90 mmHg and
proteinuria above 0.3 g/l or rise in blood
pressure above 20 mmHg from the ﬁrst
trimester of pregnancy
Clusterin isoform 2 Increased
Apolipoprotein A-I Increased
Fibronectin Increased
Angiotensinogen Increased
Galectin 3 binding Increased
Plasminogen Increased
Transferrin Increased
C4 b binding Increased
Haemopexin Increased
Blumenstein
et al. (2009b)
Control n ¼ 6 Healthy pregnancy outcome NA Vitronectin 75 kDa Increased
PE n ¼ 6 PE was deﬁned as systolic blood pressure (BP) Vitronectin 65 kDa Decreased Plasma
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Table I Continued
Study Population Selection criteria Proteins identiﬁed Change
versus
control
(/)
Sample
site
Technique used
n Mean
age+ SD
age range
Inclusion Exclusion
≥140 mm Hg and/or diastolic BP ≥ 90 mm Hg
on 2ormoreoccasions after 20weeks’ gestation
but prior to the onset of labour, or post-partum
systolic BP ≥ 140 mmHg and/or diastolic
BP ≥ 90 mm Hg post-partum on at least 2
occasions 4 h apart, combined with either
proteinuria (spot protein to creatinine ratio
≥30 mg/mmol, or 24-h urinary protein≥0.3 g/
24 h, or dipstick proteinuria ≥2+) or any
multi-organ complication
DIGEWestern blot
LC-MS/MS
a-1-antichymotrypsin (SERPINA3) Decreased
Kininogen-1 Decreased
LC-ESI-MS/MS, liquid chromatography electrospray ionization tandemmass spectrometry; 2D-GE/2DE, 2D (gel) electrophoresis; 2D-LC, 2D liquid chromatography; DIGE, differential gel electrophoresis; ELISA, enzyme-linked immunosorbent
assay; iTRAQ, isobaric tags for absolute and relative quantiﬁcation; LC-MS/MS, liquid chromatography–tandemmass spectrometry; MALDI-TOF,matrix-assisted laser desorption time-of-ﬂight; MS, mass spectrometry; n, number of participants;
PE, pre-eclampsia; Q TOF, quadrupole time of ﬂight; SD, standard deviation; SELDI-TOF, surface-enhanced laser desorption ionization time-of-ﬂight; SRM, selective reaction monitoring; 2D-LC-MS/MS, multidimensional liquid chromatography
tandem mass spectrometry; 2D-PAGE, two-dimensional polyacrylamide gel electrophoresis. IGFALS, insulin-like growth factor binding protein; MCAM, melanoma cell adhesion molecule.
aVitamin D binding protein is found on the lists of over- and under-represented proteins with different protein database accession numbers.When careful analysis of the peptide datawas donemanually, it was revealed that themajority of peptides
were under-represented in the PE plasma,whereas three peptidesmatching to a different allele (GC2, T420 K)were at a relatively higher abundance in the PE plasma. This observation also shows the potential of this proteomics workﬂow to detect
differences in isoform expression as well as the potential pitfall of interpreting isoform differences as relative abundance changes if the data are not carefully scrutinized (Blankley et al., 2009).
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Table II Methodological Quality Assessment using the QUADOMICS Tool.
Quality
criteria
Epiney et al.
(2012)
Buhimschi
et al. (2008)
Park et al.
(2008)
Johnstone
et al. (2011)
Gharesi-Fard
et al. (2010)
Blumensteinetal.
(2009a)
Watanabe et al.
(2004)
Blankley
et al. (2009)
Liu et al.
(2011)
1 N Y Y N N N N N N
2 N Y Y N N Y Y Y N
3 Y Y Y Y Y Y Y Y Y
4 Y Y Y N N Y Y N N
5 Y Y Y Y Y Y Y Y Y
6 Y Y Y Y Y Y N/A Y Y
7 Y Y Y Y Y Y Y Y Y
8 Y N Y Y Y Y Y Y Y
9 Y N Y Y Y Y Y Y Y
10 Y Y Y Y Y Y Y Y Y
11 Y Y Y Y Y Y Y N Y
12 N/A Y N N N N N N N
13 Y Y Y Y Y Y Y Y Y
14 Y Y Y Y N Y Y Y Y
15 Y Y N N/A N Y N N Y
16 Y Y N N N N Y N N
Total 13 14 13 10 9 13 12 10 11
Quality
criteria
Rasanen et al.
(2010)
Jin et al. (2008) Vascotto et al.
(2007)
Myers et al.
(2013)
Centlow et al.
(2010)
Kolla et al. (2012) Blumenstein et al.
(2009b)
1 N N Y Y Y N N
2 Y N N Y N Y Y
3 N N Y Y Y Y Y
4 Y N Y Y Y Y Y
5 Y Y Y Y Y Y Y
6 N/A Y N/A N Y Y Y
7 Y Y Y Y Y Y Y
8 Y Y Y Y Y Y Y
9 Y Y Y Y Y Y Y
10 Y Y Y Y Y Y Y
11 N Y Y Y Y N Y
12 N N N Y N N N
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et al., 2010; Rasanen et al., 2010; Johnstone et al., 2011; Liu et al., 2011;
Epiney et al., 2012; Kolla et al., 2012; Myers et al., 2013).
There were a total of 1423 patients and controls in all of the selected
studies and 192 different proteomic biomarkers for PE were identiﬁed.
Six studies investigated placental tissue (Buhimschi et al., 2008; Jin
et al., 2008; Park et al., 2008; Centlow et al., 2010; Gharesi-Fard et al.,
2010; Johnstone et al., 2011; Epiney et al., 2012), one of which also
assessed urine (Buhimschi et al., 2008). Two studies used amniotic
ﬂuid (Vascotto et al., 2007; Park et al., 2008), ﬁve used plasma (Blankley
et al., 2009; Blumenstein et al., 2009b; Liu et al., 2011; Kolla et al., 2012;
Myers et al., 2013) and ﬁnally, three used serum samples (Watanabe
et al., 2004; Blumenstein et al., 2009a; Rasanen et al., 2010). These are
summarized in Table I.
Various proteomic techniques that were used in the 16 studies
included SELDI-TOF (Surface-Enhanced Laser Desorption Ionization
Time-Of-Flight), Mass Spectrometry and MALDI-TOF (Matrix-Assisted
LaserDesorptionTime-Of-Flight),withMass Spectrometry andLC-MS/
MS (Liquid Chromatography–Tandem Mass Spectrometry) being the
most common (Table I).
Assessing the quality of the relevant studies
Out of the 16 studies, 10 were HQ, fulﬁlling 12 or more of the 16QUA-
DOMICS criteria (Watanabe et al., 2004; Vascotto et al., 2007;
Buhimschi et al., 2008; Park et al., 2008; Blumenstein et al., 2009a,b;
Centlow et al., 2010; Epiney et al., 2012; Kolla et al., 2012; Myers et al.,
2013). The remaining six studies were LQ, achieving .12 out of the
16 quality criteria (Jin et al., 2008; Blankley et al., 2009; Gharesi-Fard
et al., 2010; Rasanen et al., 2010; Johnstone et al., 2011; Liu et al.,
2011) (Table II).
Cross-referencing proteomic biomarkers
identiﬁed in primary studies of PE with
database of proteomic biomarkers for PCOS
The 192 proteomic biomarkers for PE were cross-referenced with the
PCOS database to determine if any were also differentially expressed
in PCOS. Five biomarkers were found to be differentially expressed in
women with PE and with PCOS compared with controls. Transferrin, ﬁ-
brinogen a, b and g chain variants and kininogen-1 were increased and
annexin 2 and peroxiredoxin 2 were decreased both in women with
PCOS and women with PE. For PE, these biomarkers were found in
serum, plasma and placenta, respectively,whereas in PCOS, the biomar-
kers identiﬁedwere in serum, follicular ﬂuid, ovarian and omental biopsy,
respectively.
Overlaps of the proteomic biomarkers amongst the 16 studies
included in this review were also identiﬁed and tabulated (Table III).
Discussion
This is the ﬁrst study that has identiﬁed a panel of ﬁve proteomic biomar-
kers which were similarly differentially expressed in women with PE and
in women with PCOS. These are transferrin, ﬁbrinogen a, b and g chain
variants, kininogen-1, annexin 2 and peroxiredoxin 2. These ﬁndings are
of interest but theywill need tobe validated, and there is a need for future
studies that should explore how these proteins interrelate.Wehave also
examined the interactomes of the potential biomarkers using STRING
(an online functional protein interaction network; http://string-db.
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Table III Overlaps of the proteomic biomarkers amongst the studies included in this review.
Proteins
co-expressed
Studies
Epiney
et al.
(2012)
Johnstone
et al.
(2011)
Gharesi
et al.
(2010)
Blumenstein
et al. (2009a)
Watanabe
etal. (2004)
Blankley
et al.
(2009)
Liu
et al.
(2011)
Rasanen
et al.
(2010)
Jin
et al.
(2008)
Vascotto
et al.
(2007)
Myes
et al.
(2013)
Centlow
et al.
(2010)
Kolla
et al.
(2012)
Blumenstein
et al. (2009b)
Choriogonadotrophin
subunit b/b
b-2-microglobulin
Serotransferrin/
transferrin
Calnexin
Apolipoprotein I/
Apolipoprotein A-I
a-2-HS-glycoprotein
Protein disulphide
isomerize
Heat shock protein
70/HSPA 8 (Hsc 70)
Chloride intracellular
channel protein 3
Transthyretin (TTC)
Fibronectin I/
Fibronectin
Fibrinogen g chain
Haemopexin
a-1-antichymotrypsin
(SERPINA3)
Clusterin
Coagulation factor X
Vitamin D binding
protein
Serum amyloid
P-component
a-2-macroglobulin
IGFALS
Galactin-3-binding
protein
Plasminogen
Kininigen-1
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org/).Noevidence for functional interactionsbetween thepotential bio-
markers (with the exception of the closely related ﬁbrinogen a, b and g
proteinswhichdo interactwitheachother)was found, althoughSTRING
did highlight the co-expression of ﬁbrinogen b and kininogen-1. Thus, at
present we are unable to present a pathway that rationalizes how
changes in the different candidate biomarkersmay relate to one another.
The ﬁve proteomic biomarkers identiﬁed might clarify the link
between PCOS and PE. There is a constant and evolving theme from
studies applying proteomic approaches in PCOS about the possible
role of immune regulation/inﬂammation and antioxidants in the patho-
genesis of the condition. Similarly, these two pathways have also been
implicated in the pathogenesis of PE (Tousoulis et al., 2008; Szarka
et al., 2010; Redman, 2011; Yun et al., 2012).
Annexin A2 was down-regulated both in patients with PE and PCOS,
although in PCOS, it was found in ovarian biopsies and in PE. it was in pla-
cental biopsies. It is known that Annexin A2 is the key physiological re-
ceptor for plasminogen on the extracellular surface of endothelial cells
(Gugliucci and Ghitescu, 2002). It causes ﬁbrinolysis by accelerating
tissue plasminogen activator (Kang et al., 1999) at the endothelial level,
via insulin-stimulated plasma membrane translocation of the glucose
transporterGLUT-4 (Lennon et al., 2003;Huanget al., 2004).Thedown-
regulation observed in PE tilts the coagulation/ﬁbrinolysis balance
towards enhanced coagulation and thrombosis (Gugliucci and Ghitescu,
2002;Ma et al., 2007).We thus postulate that sinceAnnexinA2 is down-
regulated both in women with PCOS and PE, it could be a strong candi-
date for a potential biomarker for the detection of PE in women with
PCOS.
Annexin A2 and ﬁbrinogen a, b and g chains are central in regulating
ﬁbrinolysis and thrombosis and their altered expressionmight represent
changes in permeability of the peripheral vessels and vasculature of the
various tissues, including ovaries, causing ﬁbrinolysis and abnormal ﬁbro-
genesis and thrombosis in PCOS (Gugliucci and Ghitescu, 2002). We
speculate that the impaired expression of these proteins may account
for the early pregnancy complications such as miscarriage and could
impinge upon the cardiovascular system in PCOSpatients due to hypoﬁ-
brinolysis and thrombophilia (Gugliucci and Ghitescu, 2002).
Transferrin was found to be up-regulated in sera of women with PE
and PCOS. It is an important b-globulin responsible for transporting
iron to various tissues and promoting cell growth and development
(Gatter et al., 1983). Transferrin also plays a vital role in pregnancy
where it is expressed signiﬁcantly in the villous syncytiotrophoblasts in
women with PE compared with those with normal pregnancies. The
cause for this substantial expression in theplacentaeof pregnancies com-
plicated by either gestational diabetes or PE could be the developing or
existing fetal stress (Kralova et al., 2008). Transferrin in high concentra-
tions can inhibit FSH to interact with its receptors on the granulosa
cells and this can affect the maturation of oocytes by decreasing the
levels of cAMP (Kawano et al., 1995). Transferrin is also known to be a
stress/acute phase response molecule. Its upsurge in both women
with PCOS and PE could be explained on the basis of the inﬂammatory
constituent of the two conditions.
Kininogen-1was found to be up-regulated both inwomenwith PE and
PCOS in plasma and omental biopsy, respectively. Kininogens play an
important role in blood coagulation by helping to position optimally pre-
kallikrein and factorXI next to factorXII and inhibiting the thrombin- and
plasmin-induced aggregation of thrombocytes (Wong and Takei, 2013).
Moreover, they are a mediator of inﬂammation and cause increases in
vascular permeability, stimulation of nociceptors, and release of other
mediators of inﬂammation (Wong and Takei, 2013). These mechanisms
havebeen implicated in thepathogenesis of bothPEandPCOS (Gugliucci
and Ghitescu, 2002; Tousoulis et al., 2008; Szarka et al., 2010; Redman,
2011; Yun et al., 2012; Cubedo et al., 2013).
Peroxiredoxin 2 was found to be down-regulated in both PE and
PCOS in placental and omental biopsy, respectively (Gatter et al.,
1983). In view of the essential role of peroxiredoxin in protecting cells
against H2O2-induced cell damage and apoptosis, down-regulation in
placentae of women with PE emphasizes the role of oxidative stress as
an important factor in the development of PE (Cubedo et al., 2013). Fur-
thermore, recent studies have advocated that oxidative stress stimulates
androgen-producing steroidogenic enzymes leading to the hyperandro-
genism observed in women with PCOS (Burton and Jauniaux, 2004).
As the proteins are the functional units within the cellular environ-
ment, analysis of proteomes provide what is presently the ﬁnest depic-
tion of disease aetiology at a molecular level.
The discovery of biomarkers poses a challenging task and this ismainly
due to the different nature of the samples tested (serum, plasma, urine,
tissue). All these samples contain proteins in abundance which reﬂects
their biological activity. It is often thought that tissue biopsy may reﬂect
the disease process more accurately; however, the low invasiveness,
low cost and easy sample collection and processing makes the use of
body ﬂuids a more attractive option in biomarker studies (Hu et al.,
2006). The key to overcome the issues with different samples and
analysis is vigilance in sample preparation, state of the art mass spe-
ctrometry, careful data processing and cautious data analysis.
One important consideration is that in our analysis, we searched for
common biomarkers (to PE and PCOS) but identiﬁed from proteomic
analyses of different tissues. This raises the question as to whether spe-
ciﬁc changes in protein (biomarker) expression in, for example, placenta,
would be accurately reﬂected in serum or plasma. Certainly, tissues are
characterized by a higher protein complexity than blood, but with the
latter is more challenging to interrogate in the initial biomarker discovery
phase due to the large dynamic range of blood-derived protein concen-
trations. Indeed, this is an important question for clinical proteomic ana-
lyses in general and not one that has been extensively addressed to date
in an evidence-based manner. A few studies relevant to different clinical
conditions (suchas PEandPCOS)haveconsideredcorrelationsbetween
levels of tissue and circulating biomarkers, with differing results. For
example, one study of individuals with abdominal aortic aneurysms
found no correlation between levels of amino-terminal pro-peptide of
type III pro-collagen between plasma and tissue (Treska and Topolcan,
2000). In contrast, a recent study of non-small lung cell carcinoma
demonstrated that GP88 (pro-granulin) is both a tissue and circulating
disease biomarker (Edelman et al., 2014), suggesting an association in ex-
pression levels. In the context of our ownwork, it would be of particular
interest to perform a future study comparing relative expression levels of
proteins in placenta, follicular ﬂuid, ovarian and omental biopsies com-
pared with serum/plasma, and determine whether under conditions
where changes in tissue expression occur, such changes are alsomanifest
in the circulation.
The various quantitative and semi-quantitative proteomic techniques
used up till now poses a challenge because of the disparate accuracy of
the results. We chose to report differential protein expression as
either up- or down-regulated which is consistent with previously pub-
lished systematic reviews of proteomic biomarkers (Baek et al., 2010)
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as there is a concern that systematic reviews and meta-analysis are inﬂu-
enced by the clinical heterogeneity. The use of inﬂammatorymarkers for
diagnosing diseases is another challenge as these markers can also be
associated with various other concomitant disease processes. This is a
limitation that is known to all biomarker studies of complex diseases
(Ling et al., 2011). It is not recommendedat this stage that thebiomarkers
identiﬁed inour studyareusedas conclusivebiomarkersof PEandPCOS.
Our results provide a frameworkonwhich futurework can be based and
validation studies can be used to better understand the pathophysio-
logical mechanisms linking PCOS and PE.
Proteomic and other ‘omic’ technologies offer a great prospective for
creating new insights into disease aetiology, but it is not without limita-
tions.The relatively slowpace atwhich researchﬁndings havebeen trans-
lated into clinical care is of a concern (Peral et al., 2009). Proteomic
techniques have a restricted ability to detect low-abundance proteins,
some of which may have diagnostic potential. Moreover, there is a risk
of false-positive results as the sample sizes are small (Solomon and
Seely, 2006). Emphasis should be placed on data assimilation from
primaryproteomic studies inorder to improve interpretationof research
ﬁndings and prospective endorsement (Hojlund et al., 2008).
All these issues highlight the fact that there should be more collabor-
ation. This would ensure data synthesis and integration (as in this review)
in order to narrow down replicated biomarkers which can be then be
validated in subsequent hypothesis-driven research.We see great signiﬁ-
cance in disseminating our ﬁndings to the scientiﬁc community as it is vital
for the progress in the area of ‘omic’ research.
Conclusion
Through integrating data from proteomic studies of PE with data from
proteomic studies of PCOS, we have for the ﬁrst time identiﬁed a
panel of ﬁve biomarkers of PE which are common to women with
PCOS; these are transferrin, ﬁbrinogen a, b and a chain variants,
kininogen-1, annexin 2 and peroxiredoxin 2. If validated, these biomar-
kers could provide a useful framework on which the knowledge base
in this area could be developed. This goal can be achieved by greater col-
laboration between clinicians, basic scientists and mathematicians.
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